Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Eric Angevin, Elena Elez, Steven J. Cohen, Jean-Luc Van Laethem, Christian Ottensmeier, Florence Joly, Isabelle Ray-Coquard, Jose A. Lopez-Martin, Luc Dirix, Jean-Pascal Machiels, Sally Clive, Neil Matthew Steven, Manjula Reddy, Brett Hall, Thomas Puchalski, Rajesh Bandekar, Helgi Van De Velde, Brenda J. Tromp, Jessica Vermeulen, Razelle Kurzrock
Institutions: Institut Gustave Roussy, Vall d'Hebron Hospital Universitari, Fox Chase Cancer Center, Erasmus Hospital, University Hospital Southampton NHS Foundation Trust, Centre François Baclesse, Centre Léon Bérard, Hospital Universitario 12 De Octubre, Cliniques Universitaires Saint-Luc, Western General Hospital, Queen Elizabeth Hospital Birmingham, Janssen Research & Development (United States), Janssen (Belgium), Janssen (Netherlands), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2606531505